The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations
Open accessAbstract
Myasthenia gravis (MG) is an autoimmune neurological disorder characterized by defective transmission at the neuromuscular junction. The incidence of the disease is 4.1 to 30 cases per million person-years, and the prevalence rate ranges from 150 to 200 cases per million. MG is considered a classic example of antibody-mediated autoimmune disease. Most patients with MG have autoantibodies against the acetylcholine receptors (AChRs). Less commonly identified autoantibodies include those targeted to muscle-specific kinase (MuSK), low-density lipoprotein receptor-related protein 4 (Lrp4), and agrin. These autoantibodies disrupt cholinergic transmission between nerve terminals and muscle fibers by causing downregulation, destruction, functional blocking of AChRs, or disrupting the clustering of AChRs in the postsynaptic membrane. The core clinical manifestation of MG is fatigable muscle weakness, which may affect ocular, bulbar, respiratory and limb muscles. Clinical manifestations vary according to the type of autoantibody, and whether a thymoma is present.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oosterhuis, H. (1997) · Cited by 2,397
Mammalian nicotinic acetylcholine receptors: from structure to function
Albuquerque, E. X., Pereira, E. F. R., Alkondon, M., & Rogers, S. W. (2009) · Physiological Reviews · doi:10.1152/physrev.00015.2008 · Cited by 1,724
Myasthenia gravis: subgroup classification and therapeutic strategies
Gilhus, N. E., & Verschuuren, J. J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00145-3 · Cited by 1,267
Hoch, W., McConville, J., Helms, S., Newsom-Davis, J., Melms, A., & Vincent, A. (2001) · Nature Medicine · doi:10.1038/85520 · Cited by 1,183
Vinuesa, C. G., Linterman, M. A., Yu, D., & MacLennan, I. C. M. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055605 · Cited by 1,141
Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells
Battaglia, M., Stabilini, A., & Roncarolo, M.-G. (2005) · Blood · doi:10.1182/blood-2004-10-3932 · Cited by 1,134
Gilhus, N. E. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1602678 · Cited by 1,048
Autoimmune Response to Acetylcholine Receptor
Patrick, J., & Lindstrom, J. (1973) · Science · doi:10.1126/science.180.4088.871 · Cited by 1,043
Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells
Stevens, T. L., Bossie, A., Sanders, V. M., Fernandez-Botran, R., Coffman, R. L., Mosmann, T. R., & Vitetta, E. S. (1988) · Nature · doi:10.1038/334255a0 · Cited by 933
BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF
Thompson, J. S., Bixler, S. A., Qian, F., Vora, K., Scott, M. L., Cachero, T. G., Hession, C., Schneider, P., Sizing, I. D., Mullen, C., et al. (2001) · Science · doi:10.1126/science.1061965 · Cited by 889
MacDonald, B. K. (2000) · Brain · doi:10.1093/brain/123.4.665 · Cited by 858 · cited 1×
“1 to 30 cases per million person-years [14,15].”
BackgroundInternational Consensus Guidance for Management of Myasthenia Gravis: 2020 Update
Narayanaswami, P., Sanders, D. B., Wolfe, G., Benatar, M., Cea, G., Evoli, A., Gilhus, N. E., Illa, I., Kuntz, N. L., Massey, J., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011124 · Cited by 813
A systematic review of population based epidemiological studies in Myasthenia Gravis
Carr, A. S., Cardwell, C. R., McCarron, P. O., & McConville, J. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-46 · Cited by 756
Lifetime course of myasthenia gravis
Grob, D., Brunner, N., Namba, T., & Pagala, M. (2008) · Muscle & Nerve · doi:10.1002/mus.20950 · Cited by 733
Lrp4 is a receptor for Agrin and forms a complex with MuSK
Kim, N., Stiegler, A. L., Cameron, T. O., Hallock, P. T., Gomez, A. M., Huang, J. H., Hubbard, S. R., Dustin, M. L., & Burden, S. J. (2008) · Cell · doi:10.1016/j.cell.2008.10.002 · Cited by 676 · cited 1×
“Phosphorylated MuSK activates a downstream signaling pathway that leads to the clustering of AChRs (Figure 1) [60].”
BackgroundNeuromuscular Junction in Myasthenia Gravis: Decreased Acetylcholine Receptors
Fambrough, D. M., Drachman, D. B., & Satyamurti, S. (1973) · Science · doi:10.1126/science.182.4109.293 · Cited by 640
Autoantibodies to low‐density lipoprotein receptor–related protein 4 in myasthenia gravis
Higuchi, O., Hamuro, J., Motomura, M., & Yamanashi, Y. (2011) · Annals of Neurology · doi:10.1002/ana.22312 · Cited by 535
The Muscle Protein Dok-7 Is Essential for Neuromuscular Synaptogenesis
Okada, K., Inoue, A., Okada, M., Murata, Y., Kakuta, S., Jigami, T., Kubo, S., Shiraishi, H., Eguchi, K., Motomura, M., et al. (2006) · Science · doi:10.1126/science.1127142 · Cited by 439
Myasthenic Antibodies Cross-Link Acetylcholine Receptors to Accelerate Degradation
Drachman, D. B., Angus, C. W., Adams, R. N., Michelson, J. D., & Hoffman, G. J. (1978) · New England Journal of Medicine · doi:10.1056/nejm197805182982004 · Cited by 437
Balandina, A., Lécart, S., Dartevelle, P., Saoudi, A., & Berrih-Aknin, S. (2005) · Blood · doi:10.1182/blood-2003-11-3900 · Cited by 429
Human regulatory B cells in health and disease: therapeutic potential
Mauri, C., & Menon, M. (2017) · Journal of Clinical Investigation · doi:10.1172/jci85113 · Cited by 418
Clinical aspects of MuSK antibody positive seronegative MG
Sanders, D. B., El-Salem, K., Massey, J. M., McConville, J., & Vincent, A. (2003) · Neurology · doi:10.1212/01.wnl.0000065882.63904.53 · Cited by 407
Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis
Pevzner, A., Schoser, B., Peters, K., Cosma, N.-C., Karakatsani, A., Schalke, B., Melms, A., & Kröger, S. (2012) · Journal of Neurology · doi:10.1007/s00415-011-6194-7 · Cited by 342
Tzartos, J. S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.2393 · Cited by 342
Zisimopoulou, P., Evangelakou, P., Tzartos, J., Lazaridis, K., Zouvelou, V., Mantegazza, R., Antozzi, C., Andreetta, F., Evoli, A., Deymeer, F., et al. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.12.004 · Cited by 329
The natural course of myasthenia gravis: a long term follow up study.
Oosterhuis, H. J. (1989) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.52.10.1121 · Cited by 326
MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4
Huijbers, M. G., Zhang, W., Klooster, R., Niks, E. H., Friese, M. B., Straasheijm, K. R., Thijssen, P. E., Vrolijk, H., Plomp, J. J., Vogels, P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313944110 · Cited by 297
Thymoma associated with autoimmune diseases: 85 cases and literature review
Bernard, C., Frih, H., Pasquet, F., Kerever, S., Jamilloux, Y., Tronc, F., Guibert, B., Isaac, S., Devouassoux‐Shisheboran, M., Chalabreysse, L., et al. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.09.005 · Cited by 292
The Mechanisms of T Cell Selection in the Thymus
Takaba, H., & Takayanagi, H. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.07.010 · Cited by 292
The Epidemiology of Myasthenia Gravis
PHILLIPS, L. H. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1254.053 · Cited by 250
The Incidence of Myasthenia Gravis: A Systematic Literature Review
McGrogan, A., Sneddon, S., & de Vries, C. S. (2010) · Neuroepidemiology · doi:10.1159/000279334 · Cited by 238
HOWARD, F. M., LENNON, V. A., FINLEY, J., MATSUMOTO, J., & ELVEBACK, L. R. (1987) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1987.tb51321.x · Cited by 236
Tanaka, A., Moriyama, M., Nakashima, H., Miyake, K., Hayashida, J., Maehara, T., Shinozaki, S., Kubo, Y., & Nakamura, S. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33320 · Cited by 229
Estrogen-mediated downregulation of AIRE influences sexual dimorphism in autoimmune diseases
Dragin, N., Bismuth, J., Cizeron-Clairac, G., Biferi, M. G., Berthault, C., Serraf, A., Nottin, R., Klatzmann, D., Cumano, A., Barkats, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81894 · Cited by 210
A Genome-Wide Association Study of Myasthenia Gravis
Renton, A. E., Pliner, H. A., Provenzano, C., Evoli, A., Ricciardi, R., Nalls, M. A., Marangi, G., Abramzon, Y., Arepalli, S., Chong, S., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4103 · Cited by 206
Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture
Koneczny, I., & Herbst, R. (2019) · Cells · doi:10.3390/cells8070671 · Cited by 194
Koneczny, I., Cossins, J., Waters, P., Beeson, D., & Vincent, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080695 · Cited by 184
Autoantibodies to Agrin in Myasthenia Gravis Patients
Zhang, B., Shen, C., Bealmear, B., Ragheb, S., Xiong, W.-C., Lewis, R. A., Lisak, R. P., & Mei, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091816 · Cited by 177
Anti-agrin autoantibodies in myasthenia gravis
Gasperi, C., Melms, A., Schoser, B., Zhang, Y., Meltoranta, J., Risson, V., Schaeffer, L., Schalke, B., & Kröger, S. (2014) · Neurology · doi:10.1212/wnl.0000000000000478 · Cited by 175
Anti‐MuSK patient antibodies disrupt the mouse neuromuscular junction
Cole, R. N., Reddel, S. W., Gervásio, O. L., & Phillips, W. D. (2008) · Annals of Neurology · doi:10.1002/ana.21371 · Cited by 174
Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis
Deymeer, F., Gungor-Tuncer, O., Yılmaz, V., Parman, Y., Serdaroglu, P., Ozdemir, C., Vincent, A., & Saruhan-Direskeneli, G. (2007) · Neurology · doi:10.1212/01.wnl.0000254620.45529.97 · Cited by 164
Roles of cytokines and T cells in the pathogenesis of myasthenia gravis
Uzawa, A., Kuwabara, S., Suzuki, S., Imai, T., Murai, H., Ozawa, Y., Yasuda, M., Nagane, Y., & Utsugisawa, K. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13546 · Cited by 160
Gradolatto, A., Nazzal, D., Truffault, F., Bismuth, J., Fadel, É., Foti, M., & Berrih‐Aknin, S. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.12.015 · Cited by 158
Thiruppathi, M., Rowin, J., Ganesh, B. B., Sheng, J. R., Prabhakar, B. S., & Meriggioli, M. N. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.09.012 · Cited by 143
Late Onset Myasthenia Gravis Is Associated with HLA DRB1*15:01 in the Norwegian Population
Maniaol, A. H., Elsais, A., Lorentzen, Å. R., Owe, J. F., Viken, M. K., Sæther, H. S., Flåm, S. T., Bråthen, G., Kampman, M. T., Midgard, R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036603 · Cited by 128
Associations between HLA and autoimmune neurological diseases with autoantibodies
Muñiz‐Castrillo, S., Vogrig, A., & Honnorat, J. (2020) · Autoimmunity Highlights · doi:10.1186/s13317-019-0124-6 · Cited by 126
Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population-Based Study
Hendricks, T. M., Bhatti, M. T., Hodge, D. O., & Chen, J. J.-W. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2019.04.017 · Cited by 124
LRP 4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients
Tzartos, J. S., Zisimopoulou, P., Rentzos, M., Karandreas, N., Zouvelou, V., Evangelakou, P., Tsonis, A., Thomaides, T., Lauria, G., Andreetta, F., et al. (2013) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.26 · Cited by 117
COURSE AND MANAGEMENT OF MYASTHENIA GRAVIS
Grob, D. (1953) · JAMA · doi:10.1001/jama.1953.02940230001001 · Cited by 115
Truffault, F., de Montpréville, V., Eymard, B., Sharshar, T., Panse, R. L., & Berrih‐Aknin, S. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8558-3 · Cited by 113
Heiden, J. A. V., Stathopoulos, P., Zhou, J. Q., Chen, L., Gilbert, T. J., Bolen, C. R., Barohn, R. J., Dimachkie, M. M., Ciafaloni, E., Broering, T. J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601415 · Cited by 109
Effects of Cytokines on Acetylcholine Receptor Expression: Implications for Myasthenia Gravis
Poëa‐Guyon, S., Christadoss, P., Panse, R. L., Guyon, T., Baets, M. H. D., Wakkach, A., Bidault, J., Tzartos, S. J., & Berrih‐Aknin, S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.5941 · Cited by 108
Clinical features of LRP4 /agrin‐antibody–positive myasthenia gravis: A multicenter study
Rivner, M. H., Quarles, B. M., Pan, J., Yu, Z., Howard, J. F., Corse, A. M., Dimachkie, M. M., Jackson, C. E., Vu, T., Small, G. A., et al. (2020) · Muscle & Nerve · doi:10.1002/mus.26985 · Cited by 103
Morgan, B. P., Chamberlain-Banoub, J. L., Neal, J., Song, W., Mizuno, M., & Harris, C. L. (2006) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2006.03205.x · Cited by 99
Vandiedonck, C., Beaurain, G., Giraud, M., Hue-Beauvais, C., Eymard, B., Tranchant, C., Gajdos, P., Dausset, J. B., & Garchon, H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406756101 · Cited by 98
Cao, Y., Amezquita, R. A., Kleinstein, S. H., Stathopoulos, P., Nowak, R. J., & O’Connor, K. C. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501339 · Cited by 94
Nationwide Population-Based Epidemiological Study of Myasthenia Gravis in Taiwan
Lai, C.-H., & Tseng, H. F. (2010) · Neuroepidemiology · doi:10.1159/000311012 · Cited by 93
Çebi, M., Durmuş, H., Aysal, F., Özkan, B., Gül, G. E., Çakar, A., Hocaoǧlu, M., Mercan, M., Yentur, S. P., Tütüncü, M., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00809 · Cited by 93
Sun, F., Ladha, S. S., Yang, L., Liu, Q., Shi, S. X.-Y., Su, N., Bomprezzi, R., & Shi, F. (2013) · Muscle & Nerve · doi:10.1002/mus.23951 · Cited by 89
HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5
Bartoccioni, E., Scuderi, F., Augugliaro, A., Ranieri, S. C., Sauchelli, D., Alboino, P., Marino, M., & Evoli, A. (2009) · Neurology · doi:10.1212/01.wnl.0000339103.08830.86 · Cited by 89
T Helper Type 17 Cells Expand in Patients with Myasthenia‐Associated Thymoma
Wang, Z., Wang, W., Chen, Y., & Wei, D. (2012) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2012.02703.x · Cited by 86
Juvenile Myasthenia Gravis: A Twenty-Year Experience
Castro, D., Derisavifard, S., Anderson, M., Greene, M., & Iannaccone, S. T. (2013) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0b013e318253a48e · Cited by 73
Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis
Yi, J. S., Guidon, A. C., Sparks, S. D., Osborne, R. J., Juel, V. C., Massey, J. M., Sanders, D. B., Weinhold, K. J., & Guptill, J. T. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.12.005 · Cited by 70
Villegas, J. A., Wassenhove, J. V., Panse, R. L., Berrih‐Aknin, S., & Dragin, N. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13591 · Cited by 69
How myasthenia gravis alters the safety factor for neuromuscular transmission
Ruff, R. L., & Lennon, V. A. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.04.038 · Cited by 65
Immune Skew of Circulating Follicular Helper T Cells Associates With Myasthenia Gravis Severity
Ashida, S., Ochi, H., Hamatani, M., Fujii, C., Kimura, K., Okada, Y., Hashi, Y., Kawamura, K., Ueno, H., Takahashi, R., et al. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000945 · Cited by 64
Childhood myasthenia: clinical subtypes and practical management
Parr, J. R., & Jayawant, S. (2007) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2007.00629.x · Cited by 62
Elevated plasma interleukin-17A in a subgroup of Myasthenia Gravis patients
Xie, Y., Li, H., Jiang, B., Li, Y., Kaminski, H. J., & Kusner, L. L. (2015) · Cytokine · doi:10.1016/j.cyto.2015.06.011 · Cited by 60
Rivner, M. H., Liu, S. M., Quarles, B. M., Fleenor, B., Shen, C., Pan, J., & Mei, L. (2016) · Muscle & Nerve · doi:10.1002/mus.25438 · Cited by 57
Vrolix, K., Fraussen, J., Losen, M. H., Stevens, J., Lazaridis, K., Molenaar, P. C., Somers, V. A., Bracho, M. A., Panse, R. L., Stinissen, P., et al. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.12.008 · Cited by 56
Kufukihara, K., Watanabe, Y., Inagaki, T., Takamatsu, K., Nakane, S., Nakahara, J., Ando, Y., & Suzuki, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-41730-z · Cited by 56
Behzad, M., Yılmaz, V., Gülşen-Parman, Y., Aysal, F., Oflazer, P., Deymeer, F., & Saruhan‐Direskeneli, G. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.08.271 · Cited by 55
Kordas, G., Lagoumintzis, G., Sideris, S., Poulas, K. A., & Tzartos, S. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108327 · Cited by 54
Muscle specific kinase autoimmune myasthenia gravis in children: A case series
Skjei, K. L., Lennon, V. A., & Kuntz, N. L. (2013) · Neuromuscular Disorders · doi:10.1016/j.nmd.2013.07.010 · Cited by 49
Saruhan‐Direskeneli, G., Hughes, T. K., Yılmaz, V., Durmuş, H., Adler, A., Behzad, M., Aysal, F., Yentur, S. P., Akalın, M. A., Doğan, Ö., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.05.003 · Cited by 46
Clinical features and evolution of juvenile myasthenia gravis in a French cohort
Barraud, C., Desguerre, I., Barnérias, C., Gitiaux, C., Boulay, C., & Chabrol, B. (2017) · Muscle & Nerve · doi:10.1002/mus.25965 · Cited by 44
In‐depth peripheral CD4+ T profile correlates with myasthenic crisis
Huan, X., Luo, S., Zhong, H., Zheng, X., Song, J., Zhou, L., Lü, J., Wang, Y., Xu, Y., Xi, J., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51312 · Cited by 38
Li, M., Han, J., Zhang, Y., Lv, J., Zhang, J., Zhao, X., Ren, L., Fang, H., Yang, J. C., Zhang, Y., et al. (2019) · European Journal of Neurology · doi:10.1111/ene.13979 · Cited by 37
Peragallo, J. H., Bitrian, E., Kupersmith, M. J., Zimprich, F., Whittaker, T. J., Lee, M. S., & Bruce, B. B. (2015) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000276 · Cited by 32
Impaired regulatory B cells in myasthenia gravis
Sheng, J. R., Rezania, K., & Soliven, B. C. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.05.004 · Cited by 32
Self-citationYi, J. S., Russo, M. A., Massey, J. M., Juel, V. C., Hobson‐Webb, L. D., Gable, K., Raja, S. M., Balderson, K., Weinhold, K. J., & Guptill, J. T. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00034 · Cited by 31
Fang, W., Li, Y., Mo, R., Wang, J., Li, Q., Ou, C.-Y., Lin, Z., Huang, Z., Feng, H., He, X.-T., et al. (2020) · Neurological Sciences · doi:10.1007/s10072-019-04146-1 · Cited by 31
Regulatory B Cells in Seropositive Myasthenia Gravis versus Healthy Controls
Karim, M. R., Zhang, H., Jiang, Y., Sun, Q., & Wang, Y. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00043 · Cited by 27
Gender and Ethnicity Based Differences in Clinical and Laboratory Features of Myasthenia Gravis
Abukhalil, F., Mehta, B. K., Saito, E. K., Mehta, S., & McMurtray, A. M. (2015) · Autoimmune Diseases · doi:10.1155/2015/197893 · Cited by 23
Cited by
JAK inhibition decreases the autoimmune burden in Down syndrome
Rachubinski, A. L., Wallace, E., Gurnee, E., Enriquez-Estrada, B. A., Worek, K. R., Smith, K. P., Araya, P., Waugh, K. A., Granrath, R. E., Britton, E., et al. (2024) · eLife · doi:10.7554/elife.99323 · Cited by 32
Metadata
- Authors
- Dresser, L., Wlodarski, R., Rezania, K., & Soliven, B.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2021-05-21
- Volume
- 10
- Issue
- 11
- Pages
- 2235
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W3165482046
- Cited by
- 475
- References
- 84
- FWCI
- 25.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.